Prosecution Insights
Last updated: October 02, 2026
Application No. 18/422,786

HALOACETHYDRAZIDES USEFUL AS AEP INHIBITORS

Final Rejection §112
Filed
Jan 25, 2024
Priority
Jul 28, 2021 — EU 21188258.4 +1 more
Examiner
COLEMAN, BRENDA LIBBY
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Hoffmann-La Roche Inc.
OA Round
2 (Final)
75%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
90%
With Interview

Examiner Intelligence

Grants 75% — above average
75%
Career Allowance Rate
1230 granted / 1643 resolved
+14.9% vs TC avg
Strong +16% interview lift
Without
With
+15.5%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
52 currently pending
Career history
1670
Total Applications
across all art units

Statute-Specific Performance

§101
3.4%
-36.6% vs TC avg
§103
8.5%
-31.5% vs TC avg
§102
15.8%
-24.2% vs TC avg
§112
52.8%
+12.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1643 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-14 and 17-19 are pending in the application. This action is in response to applicants' amendment dated August 25, 2026. Claims 10, 13 and 14 have been amended and claims 15, 16, 20 and 21 have been canceled. Response to Amendment Applicant's arguments filed August 25, 2026 have been fully considered with the following effect: The applicant's amendments and arguments are sufficient to overcome the 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph rejections, labeled paragraph 1h) and j) in the last office action, which are hereby withdrawn. However, with regards to the 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph rejections, labeled paragraph 1a), b), c), d), e), f), g) and i) of the last office action, the applicant’s amendments and remarks have been fully considered but they are not persuasive. a-g) The applicants’ stated that the Applicant respectfully disagrees and traverses the rejection where the variables R¹, R², R³, R⁴, R⁵, R⁶ and R⁷ are not defined in claim 1. They also stated that the Applicant has double-checked the file history of this Application and notes that claim 1 as it appears in this Amendment is consistent with the claims as filed and in the published Application US 20240217928 and all recited variables are shown in the formulas and are defined in the claims. However, the variables in formula I are R1, R2, R3, R4, R5, R6 and R7 which are not R¹, R², R³, R⁴, R⁵, R⁶ and R⁷ which is what is defined in claim 1. The definitions of the variables R¹, R², R³, R⁴, R⁵, R⁶ and R⁷ are to superscript variables and not R1, R2, R3, R4, R5, R6 and R7. Claims 1-9, 13, 14 and 17-19 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention, for reasons of record and stated above. i) The applicants’ stated that claims 13 and 14 have been amended to add the missing period, however, the period at the end of line 4 of each claim is still present. Claims 13 and 14 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention, for reasons of record and stated above. Allowable Subject Matter Claims 10-12 are allowed. None of the prior art of record nor a search in the pertinent art area teaches the species as set forth in claims 10-12. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRENDA L COLEMAN whose telephone number is (571)272-0665. The examiner can normally be reached Mon-Fri 10-6 (flex). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey H. Murray can be reached at 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRENDA L COLEMAN/Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Jan 25, 2024
Application Filed
May 27, 2026
Non-Final Rejection mailed — §112
Aug 25, 2026
Response Filed
Sep 09, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12740961
USE OF AN ORGANOMETALLIC COMPOUND AS A DNA-DEMETHYLATING AGENT
5y 4m to grant Granted Sep 22, 2026
Patent 12723055
PHOSPHOANTIGEN PRODRUG COMPOUNDS
5y 8m to grant Granted Sep 01, 2026
Patent 12723038
ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE
3y 6m to grant Granted Sep 01, 2026
Patent 12708629
METHODS AND COMPOSITIONS FOR REDUCING PARATHYROID LEVELS
3y 3m to grant Granted Aug 18, 2026
Patent 12709621
TYK2 INHIBITORS
3y 1m to grant Granted Aug 18, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
75%
Grant Probability
90%
With Interview (+15.5%)
2y 5m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1643 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month